摘要
目的探讨达格列净结合利拉鲁肽治疗对糖尿病肾病(diabetic nephropathy,DN)患者肾功能、胰岛素抵抗指数(homeostasis model assessment of insulin resistance,HOMA-IR)及血糖水平的影响。方法方便选取2020年6月—2025年4月盐城市第三人民医院内分泌科收治的80例DN患者作为研究对象,根据不同治疗方法分为观察组和对照组,各40例。对照组予以常规治疗结合利拉鲁肽,观察组在其基础上予以达格列净。对比两组疗效、肾功能指标、血糖指标、不良反应。结果观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组尿白蛋白与肌酐比值、尿白蛋白排泄率及24 h尿蛋白定量均低于对照组,差异均有统计学意义(P均<0.05)。治疗后,观察组HOMA-IR、空腹血糖、餐后2 h血糖水平均低于对照组,差异均有统计学意义(P均<0.05)。两组用药安全性对比,差异无统计学意义(P>0.05)。结论达格列净结合利拉鲁肽治疗DN患者,有助于提高疗效,改善肾功能、血糖水平,减轻胰岛素抵抗,用药安全性尚可。
Objective To investigate the effects of dapagliflozin combined with liraglutide on renal function,homeostasis model assessment of insulin resistance(HOMA-IR)and blood glucose level in patients with diabetic nephropathy(DN).Methods From June 2020 to April 2025,80 patients with DN admitted to the Department of Endocrinology of Yancheng Third People's Hospital were conveniently selected as the research objects.According to different treatment methods,they were divided into observation group and control group,with 40 cases in each group.The control group was given routine treatment combined with liraglutide,and the observation group was given dapagliflozin on the basis of the control group.The efficacy,renal function index and blood glucose index and adverse reaction were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the urinary microalbumin creatinine ratio and urinary albumin excretion rate and 24-hour urinary protein quantification in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).After treatment,the HOMA-IR,fasting plasma glucose and 2-hour postprandial plasma glucose levels in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).There was no significant difference in drug safety between the two groups(P>0.05).Conclusion Dapagliflozin combined with liraglutide in the treatment of DN patients is helpful to improve the curative effect,improve renal function and blood glucose level,reduce insulin resistance,and the safety of medication is acceptable.
作者
张婉露
林海玲
袁磊
ZHANG Wanlu;LIN Hailing;YUAN Lei(Department of Endocrinology,Yancheng Third People's Hospital,Yancheng 224000,Jiangsu,China)
出处
《糖尿病新世界》
2025年第21期172-175,共4页
Diabetes New World
关键词
达格列净
利拉鲁肽
糖尿病肾病
肾功能
血糖
Dapagliflozin
Liraglutide
Diabetic nephropathy
Renal function
Blood glucose
